期刊
JOURNAL OF CLINICAL MEDICINE
卷 12, 期 6, 页码 -出版社
MDPI
DOI: 10.3390/jcm12062335
关键词
AMR; antibody-mediated rejection; DSA; donor-specific antibodies; dnDSA; de novo donor-specific antibodies; complement-fixing DSA; renal transplant; kidney graft
This study evaluated the association between complement-fixing dnDSA antibodies and graft loss, as well as the possible association between non-complement-fixing antibodies and transplanted organ survival in kidney transplant recipients. The presence of C1q-binding dnDSA was significantly associated with rejection frequency and renal graft loss. These findings suggest that classifying dnDSA based on their ability to activate the complement and detecting complement-binding capacity could serve as prognostic markers for predicting AMR outcome and graft survival in kidney transplant patients who develop dnDSA.
Background: Antibody-mediated rejection (AMR) is one of the most important challenges in the context of renal transplantation, because the binding of de novo donor-specific antibodies (dnDSA) to the kidney graft triggers the activation of the complement, which in turn leads to loss of transplant. In this context, the objective of this study was to evaluate the association between complement-fixing dnDSA antibodies and graft loss as well as the possible association between non-complement-fixing antibodies and transplanted organ survival in kidney transplant recipients. Methods: Our study included a cohort of 245 transplant patients over a 5-year period at Virgen de las Nieves University Hospital (HUVN) in Granada, Spain. Results: dnDSA was observed in 26 patients. Of these patients, 17 had non-complement-fixing dnDSA and 9 had complement-fixing dnDSA. Conclusions: Our study demonstrated a significant association between the frequency of rejection and renal graft loss and the presence of C1q-binding dnDSA. Our results show the importance of the individualization of dnDSA, classifying them according to their ability to activate the complement, and suggest that the detection of complement-binding capacity by dnDSA could be used as a prognostic marker to predict AMR outcome and graft survival in kidney transplant patients who develop dnDSA.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据